Moxonidin Stada (Moxonidine)

Moxonidine selectively stimulates central imidazoline I1 receptors. This action reduces sympathetic nervous system outflow, leading to decreased peripheral vascular resistance and lower cardiac output, which together result in a reduction of arterial blood pressure.

The appropriate dose of Moxonidin Stada is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any relevant comorbidities. Patients should follow the prescriber’s instructions exactly.

Safety data for moxonidine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Moxonidine belongs to the imidazoline receptor agonist class, which lowers blood pressure by reducing sympathetic outflow. Unlike ACE inhibitors or calcium‑channel blockers, it does not directly affect the renin‑angiotensin system or calcium channels, offering an alternative mechanism that may be useful in patients who do not tolerate other classes.

Moxonidin Stada should be stored at room temperature, below 25 °C, in its original packaging. Protect the product from moisture, excessive heat and direct sunlight to maintain its stability and potency throughout its shelf life.

Moxonidin Stada is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed, unless otherwise directed by a healthcare professional.

Serious risks include severe hypotension, bradycardia, hepatic dysfunction, allergic reactions such as rash or angioedema, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience symptoms like fainting, rapid heartbeat, severe dizziness, or signs of an allergic reaction.

Moxonidin Stada is contraindicated in patients with known hypersensitivity to moxonidine or any excipients in the formulation. Caution is advised for individuals with severe renal impairment, uncontrolled heart failure, or those taking multiple antihypertensive agents that could cause excessive blood‑pressure lowering.